Tvardi Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.863 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Details
| Name | Tvardi Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 12 |
| Founded | 2017 |
| Ceo | Imran Alibhai |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1407553072 |
| Cusip | 140755307 |
| Cik | 0001346830 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Imran Alibhai Ph.D. | Chief Executive Officer and Director |
| Dan Conn J.D., M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. John Kauh M.D. | Chief Medical Officer |
| David J. Tweardy M.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael T. Lewis Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of Research & Development |
| Stephen O'Brien CPA | Vice President of Finance and Corporate Controller |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
Contact
| Address | 3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, Texas 77478, United States |
| Phone | 713 489 8654 |
| Website | https://tvarditherapeutics.com |